STML - Stemline Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow

Income Statement

Annual
All numbers in thousands
Revenue12/31/201712/31/201612/31/201512/31/2014
Total Revenue898.1991,041.354654.16335.287
Cost of Revenue50,242.38627,869.92129,458.67621,240.599
Gross Profit-49,344.187-26,828.567-28,804.516-20,905.312
Operating Expenses
Research Development----
Selling General and Administrative19,214.20712,056.898,828.8438,084.58
Non Recurring----
Others----
Total Operating Expenses69,456.59339,926.81138,287.51929,325.179
Operating Income or Loss-68,558.394-38,885.457-37,633.359-28,989.892
Income from Continuing Operations
Total Other Income/Expenses Net730557.156389.498159.917
Earnings Before Interest and Taxes-68,558.394-38,885.457-37,633.359-28,989.892
Interest Expense----
Income Before Tax-67,828.394-38,328.301-37,243.861-28,829.975
Income Tax Expense--25.296--
Minority Interest----
Net Income From Continuing Ops-67,828.394-38,303.005-37,243.861-28,829.975
Non-recurring Events
Discontinued Operations----
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income-67,828.394-38,303.005-37,243.861-28,829.975
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares-67,828.394-38,303.005-37,243.861-28,829.975